bp-1-102 and Breast-Neoplasms

bp-1-102 has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for bp-1-102 and Breast-Neoplasms

Article	Year
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking. Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7 Targeting signal transducer and activator of transcription 3 (STAT3) is a potential anticancer strategy. However, STAT3 inhibitors with good selectivity and bioavailability are rare. The aim of this study was to discover selective direct STAT3 inhibitors with good druglikeness. By the advanced multiple ligand simultaneous docking (AMLSD) method, compound 9 was designed as an orally bioavailable STAT3 inhibitor that presented superior druggability and selectivity compared with other representative STAT3 inhibitors. 9 directly and selectively inhibited the pY705 site of STAT3 with an affinity (K Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Mice, Inbred ICR; Mice, Nude; Molecular Docking Simulation; Rats; STAT3 Transcription Factor	2017

Article

Year

Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.

Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7

Targeting signal transducer and activator of transcription 3 (STAT3) is a potential anticancer strategy. However, STAT3 inhibitors with good selectivity and bioavailability are rare. The aim of this study was to discover selective direct STAT3 inhibitors with good druglikeness. By the advanced multiple ligand simultaneous docking (AMLSD) method, compound 9 was designed as an orally bioavailable STAT3 inhibitor that presented superior druggability and selectivity compared with other representative STAT3 inhibitors. 9 directly and selectively inhibited the pY705 site of STAT3 with an affinity (K

Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Mice, Inbred ICR; Mice, Nude; Molecular Docking Simulation; Rats; STAT3 Transcription Factor

2017